Neurocrine Biosciences | NBIX - Operating Expenses


Neurocrine Biosciences reported $555.6M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
AbbVie USD -2.64B 12.35B Sep/2025
Acadia Pharmaceuticals USD 242.88M 10.68M Sep/2025
Agios Pharmaceuticals USD 129.75M 9.76M Sep/2025
ALKERMES USD 1.73B 1.44B Sep/2025
Alnylam Pharmaceuticals USD 881.04M 91.16M Sep/2025
Amgen USD 5.13B 1.39B Sep/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 807.82M 259.3M Sep/2025
Cytokinetics USD 168.69M 9.58M Sep/2025
Dynavax Technologies USD 73.6M 7.41M Sep/2025
Exelixis USD 341.4M 13.29M Sep/2025
Gilead Sciences USD 4.26B 95M Sep/2025
Halozyme Therapeutics USD 136.34M 13.06M Sep/2025
Incyte USD 4.65B 3.75B Sep/2025
Ionis Pharmaceuticals USD 316.9M 4.69M Sep/2025
Neurocrine Biosciences USD 555.6M 13.7M Sep/2025
Pfizer USD 92.8B 82.47B Sep/2025
Prothena USD 42.18M 14.25M Sep/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Repligen USD 176.13M 279K Sep/2025
Sarepta Therapeutics USD 462.23M 33.28M Sep/2025
Teva Pharmaceutical Industries USD 4.22B 812M Dec/2025
Ultragenyx Pharmaceutical USD 330.82M 56.44M Sep/2025
Vertex Pharmaceuticals USD 1.84B 27.1M Sep/2025